2型糖尿病的遗留效应:早期血糖控制对未来并发症的影响
该队列研究纳入34,737例新诊断2型糖尿病且生存10年的管理式医疗患者,平均随访13.0年,考察早期不同时段HbA1c水平与未来微血管、大血管事件及死亡的关系。结果显示,诊断后第1年HbA1c≥6.5%(≥48 mmol/mol)即与微血管和大血管事件增加相关,HbA1c≥7.0%(≥53 mmol/mol)与死亡率增加相关。
要点
- 诊断后第1年HbA1c≥6.5%(≥48 mmol/mol)与未来微血管和大血管事件风险升高相关。
- 诊断后第1年HbA1c≥7.0%(≥53 mmol/mol)与死亡率升高相关。
- HbA1c≥8.0%(≥64 mmol/mol)暴露时间越长,微血管事件和死亡风险越高。
核心结论
- 新诊断2型糖尿病且生存10年的患者中,诊断后第1年HbA1c≥6.5%(≥48 mmol/mol)与更差的未来结局相关。
- 新诊断患者可能需要立即、强化治疗,以避免不可逆的长期糖尿病并发症和死亡风险。
研究设计与样本
- 管理式医疗新诊断2型糖尿病且生存10年的队列研究,1997-2013年,平均随访13.0年,N=34,737。
- 按早期暴露0-1、0-2、0-3、0-4、0-5、0-6、0-7年各时段HbA1c分层,分析未来微血管事件、大血管事件和死亡,并调整人口学、危险因素、合并症及后续HbA1c。
主要发现
- 与0-1年HbA1c<6.5%(<48 mmol/mol)相比,HbA1c 6.5%至<7.0%(48至<53 mmol/mol)微血管事件风险比为1.204(95%CI 1.063-1.365)。
- 与0-1年HbA1c<6.5%(<48 mmol/mol)相比,HbA1c 7.0%至<8.0%(53至<64 mmol/mol)死亡风险比为1.290(95%CI 1.104-1.507)。
- HbA1c≥8.0%(≥64 mmol/mol)暴露时间越长,微血管事件和死亡风险越高。
关键数值与推荐
- 早期暴露0-1年HbA1c分层:<6.5%(<48 mmol/mol)、6.5%至<7.0%(48至<53 mmol/mol)、7.0%至<8.0%(53至<64 mmol/mol)、8.0%至<9.0%(64至<75 mmol/mol)、≥9.0%(≥75 mmol/mol)。
- HbA1c 6.5%至<7.0%(48至<53 mmol/mol)微血管事件风险比1.204(95%CI 1.063-1.365)。
- HbA1c 7.0%至<8.0%(53至<64 mmol/mol)死亡风险比1.290(95%CI 1.104-1.507)。
临床怎么用
- 对新诊断2型糖尿病患者,诊断后第1年即将HbA1c控制在<6.5%(<48 mmol/mol)可能与更好的长期结局相关。
- 原文提出新诊断患者可能需要立即、强化治疗,以避免不可逆的长期并发症和死亡风险。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine for a legacy effect of early glycemic control on diabetic complications and death. RESEARCH DESIGN AND METHODS: This cohort study of managed care patients with newly diagnosed type 2 diabetes and 10 years of survival (1997-2013, average follow-up 13.0 years, N = 34,737) examined associations between HbA1c <6.5% (<48 mmol/mol), 6.5% to <7.0% (48 to <53 mmol/mol), 7.0% to <8.0% (53 to <64 mmol/mol), 8.0% to <9.0% (64 to <75 mmol/mol), or ≥9.0% (≥75 mmol/mol) for various periods of early exposure (0-1, 0-2, 0-3, 0-4, 0-5, 0-6, and 0-7 years) and incident future microvascular (end-stage renal disease, advanced eye disease, amputation) and macrovascular (stroke, heart disease/failure, vascular disease) events and death, adjusting for demographics, risk factors, comorbidities, and later HbA1c. RESULTS: Compared with HbA1c <6.5% (<48 mmol/mol) for the 0-to-1-year early exposure period, HbA1c levels ≥6.5% (≥48 mmol/mol) were associated with increased microvascular and macrovascular events (e.g., HbA1c 6.5% to <7.0% [48 to <53 mmol/mol] microvascular: hazard ratio 1.204 [95% CI 1.063-1.365]), and HbA1c levels ≥7.0% (≥53 mmol/mol) were associated with increased mortality (e.g., HbA1c 7.0% to <8.0% [53 to <64 mmol/mol]: 1.290 [1.104-1.507]). Longer periods of exposure to HbA1c levels ≥8.0% (≥64 mmol/mol) were associated with increasing microvascular event and mortality risk. CONCLUSIONS: Among patients with newly diagnosed diabetes and 10 years of survival, HbA1c levels ≥6.5% (≥48 mmol/mol) for the 1st year after diagnosis were associated with worse outcomes. Immediate, intensive treatment for newly diagnosed patients may be necessary to avoid irremediable long-term risk for diabetic complications and mortality.
引用
- Laiteerapong N, Ham SA, Gao Y, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2018. PMID: 30104301. doi:10.2337/dc17-1144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。